Back
LYFE SCIENCES
Project: HERA
NM_006361.6:c.567C>T
p.Asn189=  ·  HOXB13
ACMG/AMP
Starting
Initialising…
0%
Legacy Engine
Processing…
Classification rationale
1

NM_006361.6:c.567C>T is a synonymous variant in HOXB13 (p.Asn189=) that does not alter the amino acid sequence.

2

This variant is extremely rare in population databases, present at an allele frequency of 0.00991% in gnomAD v2.1 (28/282,626 alleles) and 0.00452% in gnomAD v4.1 (73/1,614,196 alleles), with no homozygotes observed, satisfying PM2 at supporting level.

gnomad_v2 ↗ gnomad_v4 ↗
3

Multiple reputable clinical diagnostic laboratories (8 independent submissions) have classified this variant as Benign or Likely benign in ClinVar (VariationID 483492), with the underlying variant-specific evidence not publicly available for independent evaluation, satisfying BP6 at supporting level.

clinvar ↗
4

SpliceAI predicts no splicing impact (max delta score = 0.00), consistent with the synonymous nature of this variant.

spliceai ↗
5

No functional studies, cosegregation data, de novo observations, case-control studies, or computational evidence supporting pathogenicity have been identified for this variant.

6

The variant lies at codon 189, outside the HOXB13 homeodomain (aa 195-254), and does not fall within a known mutational hotspot or functionally critical domain.

7

Bulk evidence is sparse: one supporting pathogenic criterion (PM2) and one supporting benign criterion (BP6) are met, yielding a net indeterminate ACMG/AMP classification by strict criteria counting. However, the unanimous benign/likely benign consensus from 8 independent clinical laboratories strongly supports a benign interpretation.

clinvar ↗ gnomad_v2 ↗ gnomad_v4 ↗
Applied criteria
Met
Not met
Not assessed
N/A
Very strong
Strong
Moderate
Supporting
Pathogenic evidence
PVS
PVS1
PS
PS1
PS2
PS3
PS4
PM
PM1
PM2
PM3
PM4
PM5
PM6
PP
PP1
PP2
PP3
PP4
PP5
Benign evidence
BA
BA1
BS
BS1
BS2
BS3
BS4
BP
BP1
BP2
BP3
BP4
BP5
BP6
BP7
PVS1
Rationale
Select a criterion to inspect its explanation.
Evidence used
Gaps remaining
Rule
Publications
Research and evidence
gnomAD v2.1 evidence
v2.1
gnomAD v4.1 evidence
v4.1
01
Population
gnomAD v2.1This variant is present in gnomAD v2.1 (AF= 9.90709e-05; MAF= 0.00991%, 28/282626 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0.00100152; MAF= 0.10015%, 25/24962 alleles, homozygotes = 0); grpmax FAF= 0.00071547.
gnomAD v4.1This variant is present in gnomAD v4.1 (AF= 4.52238e-05; MAF= 0.00452%, 73/1614196 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0.00074611; MAF= 0.07461%, 56/75056 alleles, homozygotes = 0); grpmax FAF= 0.00058932.
gnomAD CanadaAvailable
ClinVar evidence
02
ClinVar
This variant has been reported in ClinVar as Likely benign (4 clinical laboratories) and as Benign (3 clinical laboratories) and as benign (1 clinical laboratory). (ClinVarID = 483492)
Functional evidence
03
Functional
OncoKB: Unknown Oncogenic Effect
OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.
In silico evidence
04
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).
COSMIC evidence
05
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Cancer hotspots evidence
06
Cancer hotspots Not found
This variant does not lie in a statistically significant hotspot.